相关实验视频

Updated: Jul 2, 2025

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

26.8K

通过使用临床试验数据对主导性遗传性阿尔茨海默病的临床试验数据进行潜伏类分析,检查粉样蛋白减少作为替代终点

Guoqiao Wang1, Yan Li1, Chengjie Xiong1

  • 1Washington University, School of Medicine, St. Louis, Missouri, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 24, 2024
PubMed
概括

在阿尔茨海默氏症试验中使用隐性类分析确定的粉样蛋白减少与更好的临床和认知结果有关. 这支持使用粉样蛋白PET扫描作为治疗疗效的替代生物标志物.

关键词:
主要继承的阿尔茨海默氏症网络自体主导性阿尔茨海默氏病这里是Gantenerumab的位置.隐性类分析 隐性类分析这里是Solanezumab.替代生物标志物替代生物标志物

更多相关视频

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

3.8K
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.0K

相关概念视频

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189